Curriculum Vitae

Adam Di Dio M.D.

Diplomate, American Board of Psychiatry & Neurology

Diplomate, American Board of Electrodiagnostic Medicine

Fellow, American Association of Neuromuscular & Electrodiagnostic Medicine

FPM

A Multi-Disciplinary Clinic

Tel: (727) 518-2977

Fax: (727) 518-0010

www.floridaphysicalmedicine.com

Professional Experience

January 2015 – Present	Practicing Neurologist Florida Physical Medicine 2200 West Bay Drive Largo, FL 33770 750 94th Avenue North #202 St. Petersburg, FL 33770
July 2006 – May 2017	Practicing Neurologist Central Neurology 2201 Central Avenue, Suite 200 St. Petersburg, FL 33713
January 2014 – January 2016	Chief of Medicine Bayfront Medical Center 701 6th Street South St. Petersburg, FL 33701
January 2014 – January 2016	Quality Improvement Committee – Vice Chair Bayfront Medical Center 701 6th Street South St. Petersburg, FL 33701
March 2014 – Present	Examiner for Retired NFL players, providing Medical Examinations and Expert opinion at request of various law firms. Central Neurology 2201 Central Avenue, Suite 200 St. Petersburg, FL 33713
Sept 2009 – March 2011	Southeast Examining Neurologist for NFL Player Benefit Association – Head Injury/Concussion Program Central Neurology 2201 Central Avenue, Suite 200 St. Petersburg, FL 33713
Fall 2011 – Jan 2014	Co-director Comprehensive Stroke Program HCA Northside Hospital 6000 49th St. North

	St. Petersburg, FL 33709
Summer 2012 – May 2017	St. Anthony's Concussion/Head Injury Prevention & Management Initiative for student athletes - Examining Neurologist Central Neurology 2201 Central Avenue, Suite 200 St. Petersburg, FL 33713
Spring 2007 – 2013	Co-director – Amyotrophic Lateral Sclerosis Clinic Suncoast Medical Clinic 2201 Central Avenue, Suite 200 St. Petersburg, FL 33701
July 2006 – May 2017	Investigator Suncoast Neuroscience Associates 2201 Central Avenue, Suite 301 St. Petersburg, FL 33713

Education

July 2005 – July 2006	Clinical Neurophysiology Fellow The Mount Sinai Medical Center; NY, NY
June 2004 – June 2005	Chief Resident of Neurology The Mount Sinai Medical Center, NY, NY
July 2002 – June 2005	Neurology Housestaff Physician The Mount Sinai Medical Center; NY, NY
July 2001-July 2002	Medical Intern North Shore University Hospital; Manhasset, NY
May 2001	Doctor of Medicine State University of New York - Upstate Medical University (SUNY Upstate); Syracuse, New York
May 1997	Bachelor of Science Emory University; Atlanta, Georgia

	MAJOR: Anthropology and Human Biology

Credentials

May 2008 – Present	Diplomate – American Board of Electrodiagnostic Medicine
Jan 2007 – Present	Diplomate – American Board of Psychiatry & Neurology

Licensure & Professional Memberships

2014 – Present	North American Brain Injury Society
2014 – 2016	American Medical Association
2005 – Present	American Academy of Neurology
May 2008 - Present	American Association of Neuromuscular and Electrodiagnostic Medicine - Fellow
May 2008 - Present	Diplomate in Electrodiagnostic Medicine, American Board of Electrodiagnostic Medicine
January 2007 - Present	Diplomate in Neurology, American Board of Psychiatry and Neurology
September 2005 – Present	Florida State License (ME94300): Medicine & Surgery
July 2005 – Present	National Institute of Health Stroke Scale Certification
July 2003 – Present	Drug Enforcement Administration
June 2002 – Present	New York State License (225702): Medicine & Surgery

Awards & Honors

September 2014	Top 10 Doctor in Neurology Award – Tampa Bay Area
Fall 2012	2012 Patient Choice Award
June 2004 – June 2005	Chief Resident of Neurology The Mount Sinai Medical Center, NY, NY
March 2005	Dr. David Coddon Memorial Headache Fellowship Award / The 15th Annual Headache Cooperative of New England Headache Symposium; Stowe, Vermont
September 2004	National Neurology Resident Scholar Epilepsy: A Clinical Dialogue Toronto, Canada
March 1997	Anthropology Honor Society Inductee Emory University
1993 -1997	Academic Scholarship Emory University

Special Skills

- Electromyography/Nerve Conduction Studies
- Single Fiber Electromyography
- Electroencephalogram interpretation
- Evoked Potentials interpretation
- Botulinum toxin injections
- Punch Skin Biopsies for small fiber polyneuropathy
- Fluent in Spanish (written & spoken

Teaching Experience

Past	Grand Rounds annually – Concussion/TBI Bayfront Medical Center 701 6th Street South St. Petersburg, FL 33701
Past	Northside Hospital Family Practice Residency – Monthly case presentation/review and annual lecture series HCA Northside Hospital 6000 49th St N, St. Petersburg, FL 33709
July 2005 – December 2005	Instructor - Brain and Behavior Course for Medical Students; The Mount Sinai School of Medicine, NY, NY
June 2004 – June 2005	Chief Resident of Neurology The Mount Sinai Medical Center, NY, NY
2001	Teacher's assistant for Neuroanatomy Laboratory State University of New York - Upstate Medical University (SUNY Upstate); Syracuse, New York

Publications

September 2007	DiDio, Adam S. & Fields, Madeline C. (2005). **Palinacousis – Auditory Perseveration: Two Cases and a Review of the Literature**. Epilepsy, September 2007
December 2005	DiDio, Adam S. & Simpson, David M. **Picturing Freedom of Movement: A Practical Approach to Alleviating Spasticity.** Practical Neurology, 2005; 4(12): 44-48
April 2005	DiDio, Adam S. & Koller, William C. (2005). **History of Essential Tremor**. In K.E. Lyons & R. Pahwa (Eds.). Handbook of Essential Tremor and Other Tremor Disorders (pp. 3-13). Boca Raton, Fl: Taylor & Francis Group

Clinical Trail-related Assessment Experience

- mMIDI
- NIHSS
- Barthel
- EDSS
- CGI
- Glasgow
- Hachinski
- Hoehn & Yahr
- MMSE
- Rankin
- Visual Analog Scale
- International RLS

Past Clinical Research

July 2000 –March 2001	Principal investigator: Burk Jubelt, M.D., Neurology Dept. Chair; SUNY Upstate
Summer 1996	Laboratory Research Assistant: Boron Neutron Capture Therapy Principal investigator: Dr. Darrell Joel, Director of Animal Studies Brookhaven Ntl. Laboratory, Upton, NY

Recent Clinical Research

Updated 25JUN2015

Protocol GAL–MCI–301: An Open–Label Study to Assess the Long – Term Safety and Tolerability of *** in the Treatment of Mild Cognitive Impairment

Protocol SENTIS: Safety and Efficacy of *** Technology in Ischemic Stroke

Protocol SCION: Study of Care Intensity and Outcomes in ***

Protocol SP792: A Multi – Center, Randomized, Double – Blind, Placebo – Controlled, Five – Arm Parallel – Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of *** in Subjects with Idiopathic Restless Legs Syndrome

Protocol SP824: A Phase 3B, Open – Label, Multicenter, Multinational Trial to Assess the Tolerability of Switching Subjects from ***, *** or *** to the *** Transdermal System and Its Effect on Symptoms in Subjects with Idiopathic Parkinson's Disease

Protocol 100013: TREAT RLS PRN A 12–Week Double–Blind, Placebo –Controlled Study to Assess the Tolerability, Efficacy and Safety of *** Dosed PRN in Subjects with Restless Legs Syndrome (RLS) who Respond to Open – Label Treatment with ***

Protocol AMEND ONO-2506POU010: A Double – Blind, Phase II, Safety and Efficacy Evaluation of *** in Patients with Mild to Moderate Alzheimer's Disease

Protocol VML – 251 – 3MRM02: A Double – Blind, Placebo – Controlled, Parallel Group Study, With an Open – Label Extension Phase, to Assess the Efficacy,

Tolerability and Safety of Oral *** in the Prevention of Menstrual–Related Migraine (MRM) Headaches in a "Difficult To Treat" Population

Protocol AIMS: Phase IV, Open – Label, Multi – Center Trial to Evaluate the Efficacy of *** 12.5 mg Intervention at Onset of Migraine Pain

A Double – Blind, Multicenter, Randomized, Placebo – Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Treatment with 3000 mg/day (Pediatric Target Dose of 60 mg/kg/day) Oral *** in Adult and Pediatric Subjects (4 – 65 years) Suffering from Idiopathic Generalized Tonic – Clonic Seizures

Protocol PRO – 513301: A Multi – Center, Prospective, Randomized, Double – Blind, Parallel Group, Single Dose, Placebo – Controlled Study of the Efficacy and Safety of *** (50 mg *** Powder for Oral Solution) Compared to Placebo in Adult Subjects with Migraine Attacks.

Protocol 60201 – 0433: Prospective, Double–Blind, Placebo–Controlled, Randomized, Multi–Center Trial with a Double–Blind Parallel–Group Extension Period to Investigate the Efficacy and Safety of Different Doses of *** in the Treatment of Blepharospasm

Protocol 60201 – 0408: Prospective, Double–Blind, Placebo–Controlled, Randomized, Multi–Center Trial with a Double–Blind Parallel–Group Extension Period to Investigate the Efficacy and Safety of Different Doses of *** in the Treatment of Cervical Dystonia

Protocol 81 – 0045: A Phase 3 Multicenter, Randomized, Double – Blind, Placebo – Controlled Study of the Safety and Efficacy of *** Extended Release Tablets in the Treatment of Patients with Postherpetic Neuralgia

Protocol 81 – 0046: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of *** Extended Release Tablets in the Treatment of Patients with Painful Diabetic Peripheral Neuropathy

Protocol E2007 – A001 – 302: A Multi – Center, Randomized, Double – Blind, Placebo – Controlled, Parallel Group Study of the Efficacy, Safety and Tolerability of *** in *** Treated Parkinson's Disease Patients with Motor Fluctuations

Protocol MEM 1003 – 004: A Multicenter, Randomized, Double – Blind, Placebo – Controlled Study to Evaluate Safety and Efficacy of *** in Patients with Mild to Moderate Alzheimer's Disease

Protocol COG 22029: A Randomized, Double–Blind, Placebo–Controlled, Dose – Titration Study to Assess the Safety, Tolerability, and Efficacy of *** in Persons with Multiple Sclerosis with Cognitive Impairment

Protocol SP889 RECOVER: Efficacy of ***: Phase 3B, Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Trial to Evaluate the Effect of the 24-Hour Transdermal Delivery of *** on the Control of Early Morning Motor Function, Sleep Quality, Nocturnal Symptoms, and Non-Motor Symptoms in Subjects with Idiopathic Parkinson's Disease

Protocol SP915: Long-Term Extension of RECOVER: A Multicenter, Multinational, Phase 3B, Open-Label Extension Trail to Evaluate the Long-Term Effect of the 24-Hour Transdermal Delivery of *** on Motor Function, Sleep Quality, and Nocturnal and Non-Motor Symptoms in Subjects with Idiopathic Parkinson's Disease

Protocol MBP8298-SP-03: MAESTRO-03: A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of *** in Subjects with Secondary Progressive Multiple Sclerosis

Protocol N01280: A Multi-Center, Double-Blind, Historical Control, Randomized Conversion to Monotherapy Study with *** XR for Treatment of Partial Onset Seizures

Protocol N01281: An Open-Label, Long-Term Follow-Up Study with *** XR for Treatment of Partial-Onset Seizures

Protocol ACP-103-012: A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of *** in the Treatment of Psychosis in Parkinson's Disease

Protocol ACP-103-015: A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of *** in Treatment of Psychosis in Parkinson's Disease

Protocol E2007-A0001-218: A Multicenter, Double-Blind, Placebo-Controlled, Dose-Tolerability Titration Study to Evaluate the Efficacy and Safety of *** in Patients with Post-Herpetic Neuralgia (PHN)

Protocol E2007-G000-227: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of *** in Patients with Painful Diabetic Neuropathy

Protocol S.T.A.R.T: Success of Titration, Analgesics, and B.E.T.A. Nurses Support on Acceptance Rates in Early MS Treatment with *** (START with *** Study)

Protocol CARISEPY 2008: A Randomized, Double-Blind, Placebo Controlled, Crossover Study to Evaluate the Efficacy and Safety of *** in the Treatment of Essential Tremor

Protocol TXA107977: A Long-Term Safety Study of a Combination Product Containing *** and *** for the Treatment of Migraine in Adolescents.

Protocol PM028: A Randomized, Controlled, Open-Label Parallel Group Study to Evaluate the Effect of Regularly Scheduled Neutralizing Antibody Testing on Treatment Patterns versus Usual Care in High-Dose Interferon Treated Subjects

Protocol AVA102672: A 54-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Effects of *** (Extended Release Tablets) as Adjunctive Therapy to *** on Cognition and Overall Clinical Response in APOE 4-Stratisfied Subjects with Mild to Moderate Alzheimer's Diesease (REFLECT-2)

Protocol E2007-G000-228: A Multi-center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of *** in Patients with Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

Protocol EHE 1100: Observational Study on Costs and Caregiver Burden in Alzheimer's Disease

Protocol ABT-089: A Randomized, Double-Blind, Placebo-Controlled Study Using a Bayesian Adaptive Design to Evaluate the Efficacy and Safety of *** in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Protocol 108MS302: A Multicenter, Open-Label, Immunogenicity, and Safety Study of *** Administered Subcutaneously to Subjects with Relapsing Multiple Sclerosis

Protocol 109MS302: A Randomized, Multicenter, Placebo-Controlled and Active Reference *** Comparison Study to Evaluate the Efficacy and Safety of *** in subjects With Relapsing-Remitting Multiple Sclerosis

Protocol PDY5807: A Multi-Center, Randomized, Double-Blind, Placebo Controlled study of the Effect of *** at two doses for 24 weeks treatment on the rate of regeneration of epidermal nerve fibers in patients with mild diabetic peripheral neuropathy

Protocol CAMMS32400507: A Phase 3, Randomized, Rater-and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose *** to Three-Times Weekly Subcutaneous *** in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Relapsed On Therapy

Protocol 07-AVR-123: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy, and to Determine the Pharmacokinetics of Two Doses of *** in the Treatment of Pseudobulbar Affect (PBA) in Patients with Amyotrophic Lateral Sclerosis and Multiple Sclerosis

Protocol SP921: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 5-Arm, Parallel-Group Trial to Assess *** System Dose Response in Subjects with Advanced Stage Parkinson's Disease

Protocol 049-00: A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of *** for Migraine Prophylaxis in Patients with Episodic Migraine

Protocol ELN115727-301: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of *** In Subjects with Mild to Moderate Alzheimer's Disease Who are Apolipoprotein E4 Non-Carriers

Protocol ELN115727-302: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of *** In Subjects with Mild to Moderate Alzheimer's Disease who are Apolipoprotein E4 Carriers

Protocol ELN115727-351: A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment of *** in Subjects with Alzheimer's Disease who Participated in Study ELN115727-301 or in Study ELN115727-302

Protocol Alz.1.C/C: A Randomized Controlled Trial to Assess the Efficacy of *** in Patients with Mild to Moderate Alzheimer's Disease using Alzheimer's Disease Medication

Protocol B1451027: A Phase 3, Multi-center, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Tolerability of *** for Up to 26-weeks in Patients with Mild to Moderate Alzheimer's Disease

Protocol IPX066-BO9-02: A Study to Evaluate the Safety and Efficacy of *** In Advanced Parkinson's Disease

Protocol IPX066-BO8-05: A Placebo-Controlled Study to Evaluate the Safety and Efficacy of *** In Subjects with Parkinson's Disease

Protocol DRI10566: A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of *** 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis

Protocol HMR1726/EFC6260 (TOPIC): An International, Multi-center, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with *** 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis

Protocol 105MS301: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of *** in Subjects with Relapsing Multiple Sclerosis

Protocol 109MS303: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of *** Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis

Protocol C25608/3056/BP/US: A Randomized, Double-Blind, Active-Controlled Crossover Study to Evaluate the Efficacy and Safety of *** Tablets Compared With Immediate-Release *** for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Pain, Followed by a 12-Week Open-Label Extension to Evaluate the Impact of *** Tablets on Patient Outcomes

Protocol 07-01-02: The E-STIM Trial: A Randomized, Double-Blind, Multicenter Trial Comparing the Efficacy of *** to a Control for the Treatment of Chronic Lower Back Pain

Protocol Droxidopa-301: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Induction-Design Study to Assess the Clinical Effect of *** in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Protocol Droxidopa-304: A Multi-Center, One Year Open-Label Study to Assess the Long-Term Safety of *** in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension

Protocol PM030: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of *** on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients with a First Episode of Acute Optic Neuritis (AON).

Protocol 101MS325: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy *** or *** to *** in Subjects with Relapsing Remitting Multiple Sclerosis

Protocol R331333PAI4001: A Prospective, Multi-Center, Observational Registry of Patients with Prescription Medications Containing *** Immediate Release for the Treatment of Pain

Protocol CO-200-201: The Effect of the Dose of *** on the Efficacy, Safety, and Tolerability in Subjects with the Relapsing Remitting Form of Multiple Sclerosis: A Phase 2 Randomized, Double-Blind, Four-Arm, Parallel, Placebo-Controlled and Active Descriptive-Comparator, 40-Week Trial

Protocol IMPX066-09-03: An Open-Label Extension of the Safety and Utility of *** in Subjects with Parkinson's Disease

Protocol Y-47-52844-003: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of *** in the Control of Nausea and Vomiting During Initiation and Continued Treatment with Subcutaneous *** in ***-Naïve Subjects with Parkinson's Disease Suffering from Acute Intermittent "Off" Episodes, with Phased Withdrawal of Subjects from *** to Placebo.

Protocol 101MS402: TYGRIS: *** Global Observational Program in Safety.

Protocol ALO-01-10-4003: A Multi-center, Primary Care-Based, Open-Label, Study to Assess the Success of Converting Opioid Experienced Patients, with Chronic, Moderate to Severe Pain, to *** Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse and Diversion.

A randomized, double-blind, sham-stimulation controlled study of the application of magnetic fields using the *** device for the treatment of Parkinson's Disease.

Protocol FTY720DUS01, EPOC: A 6-month, Randomized, Active Comparator, Open-Label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of *** 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy.

Protocol MRZ 6021-4066-5(XCiDaBLE): A Phase IV, Prospective, Observational Trial Evaluating Xeomin (Incobotulinumtoxin A) for Cervical Dystonia or Blepharospasm in the United States. Merz Pharmaceuticals

Protocol XP-B-089: A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of *** in Subjects with Spasticity due to Multiple Sclerosis.

Protocol XP-B-091: An Open Label, 26-Week Study Assessing *** Safety and Efficacy in Subjects with Spasticity Associated with Multiple Sclerosis.

Protocol EFC6058 (TERACLES): A multi-center double blind parallel-group placebo-controlled study of the efficacy and safety of *** in patients with relapsing multiple sclerosis who are treated with interferon-beta.

Protocol 101JC402 (STRATIFY-2): JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with ***.

Protocol 11-AVR-130 (PRIME): A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-Finding Study to Assess the Safety and Efficacy of Three Dose Levels of *** in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis.

Protocol DER401: Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral *** Extended Release Tablets (5 mg and 10 mg twice daily) in Patients with Multiple Sclerosis.

Protocol ACP-103-020: A Multi-Center, Placebo-Controlled, Double-blind Trial to Examine the Safety and Efficacy of *** in the Treatment of Psychosis in Parkinson's Disease.

Protocol CFTY720D2403: Long-term, prospective, observational, multinational, parallel-cohort study monitoring safety in patients with MS newly started with *** once daily or treated with another approved disease-modifying therapy.

Protocol SP953: Named Patient Program with *** System (Phase 4).

Protocol Acadia ACP-103-015: A multi-center, open label extension study to examine the safety and tolerability of *** in the treatment of psychosis in Parkinson's disease

Protocol CFTY720DUS09 (PREFERMS): A 12-month, Prospective, Randomized, active-controlled, open-label study to evaluate the patient retention of *** vs. approved first-line disease modifying therapies in adults who are in early stages of treatment for relapsing remitting Multiple Sclerosis.

Protocol CFTY720I2201 (FORCIDP): A double-blind, randomized, multicenter, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 0.5mg *** administered orally once daily versus placebo in patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Protocol TVP-1012/PM106 (MODERATO): A 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to assess the effect of *** on cognition in patients with Parkinson's Disease.

Protocol LAQ-MS-305 (CONCERTO): A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of *** (.06mg/day or 1.2mg/day) in subjects with relapsing remitting multiple sclerosis.

Protocol CBAF312A2304 (EXPAND): A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of *** in patients with secondary progressive multiple sclerosis

Protocol CFTY720D2402 (ADONIS): A 48-week, double-blind, randomized, multi-center, parallel-group study comparing structural changes in the retina and evolution of visual function after immediate versus delayed treatment with *** in patients with acute demyelinating optic neuritis

Protocol 109MS403 (MANAGE): A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Receiving Oral ***

Protocol 12-AVR-401(PRISM II): A Study to Assess the Safety, Tolerability and Effectiveness of *** in the Treatment of Pseudobulbar Affect (PBA)

Protocol GA-MS-303 (GLACIER): An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of *** 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects with Relapsing-Remitting Multiple Sclerosis

Protocol 1282013: Normal Values of Epidermal Nerve Fiber Density in the Upper Extremity.

Protocol 109-MS-401 (ESTEEM): A Multicenter, Global, Observational Study to Collect information on Safety and to Document the Drug Utilization of *** When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis

Protocol LSP13567 (TERI-PRO) : A Prospective Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of *** Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients

Precision Med 4800: A Single or Multiple Visit Protocol for Collection of DNA/RNA/SERUM/PLASMA/CSF in Amyotrophic Lateral Sclerosis and Related Disorders

Precision Med 8009(SAMPLE) : A Longitudinal Cognition Follow-up and Serial DNA/RNA/SERUM/PLASMA/CSF Banking in Subjects with MCI or Mild Alzheimer's Disease

Protocol CLR-11_03 (BASIS): A Double-Blind, Randomized, Placebo-Controlled Parallel Group Trial to Evaluate the Duration of Action of *** in Subjects with Spasticity due to Multiple Sclerosis (MS)

Protocol 109MS404 (RESPOND): A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of *** Delayed-Release Capsules in Patients with Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate

Protocol 1222014: The Assessment of the Affect of Fixative Choices for Use in Evaluating Epidermal Nerve Fiber Density Results

Protocol D5010C00009 (AMARANTH): A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of ** in Early Alzheimer's Disease

Protocol BAN2401-G000-201: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of ** in Subjects With Early Alzheimer's Disease

Protocol DS5565-A-E312: An Open-Label Extension Study of DS-5565 For 52 Weeks In Pain Associated With Fibromyalgia

Protocol TV-45070-CNS-20013: A phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients with Postherpetic Neuralgia